Tandem Autologous Stem Cell Transplantation for Patients with Primary Refractory or Poor Risk Recurrent Hodgkin Lymphoma
Open Access
- 1 May 2007
- journal article
- clinical trial
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 13 (5) , 594-600
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory hodgkin disease: A southwest oncology group phase II trialTransplantation and Cellular Therapy, 2003
- High‐dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphomaCancer, 2003
- Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR)Bone Marrow Transplantation, 2001
- Feasibility of tandem autologous stem-cell transplantation (ASCT) in induction failure or very unfavorable (UF) relapse from Hodgkin's disease (HD)Annals of Oncology, 1999
- Regimen-related toxicity and non-relapse mortality with high-dose cyclophosphamide, carmustine (BCNU) and etoposide (VP16-213) (CBV) and CBV plus cisplatin (CBVP) followed by autologous stem cell transplantation in patients with Hodgkin’s diseaseBone Marrow Transplantation, 1999
- Problems in Hodgkin’s Disease ManagementBlood, 1999
- Single and double autotransplants for relapsing/refractory Hodgkin’s disease: results of two consecutive trialsBone Marrow Transplantation, 1997
- Intensive therapy with cyclophosphamide, carmustine, etoposide +/- cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy [see comments]Blood, 1994
- Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study.Journal of Clinical Oncology, 1990
- High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease.Journal of Clinical Oncology, 1990